EXUMA Biotech

Preparative Lymphodepleting Chemotherapy – Biology & Toxicity Autologous and allogeneic CAR-T cell regimens incorporate lymphodepleting chemotherapy which supports the expansion of the therapy. Chemotherapy increases the risk of opportunistic infections and confounds the diagnosis of CRS/ICANs contributing to the requirement for patients to be in proximity of tertiary care centers.Lymphodepleting Chemotherapy Direct and Indirect Effects […]

In 2015, EXUMA initiated ambitious efforts to discover platform technologies that could enablecell and gene therapies to deliver their full potential to patients. EXUMA’s Platforms Enhance the Efficacy, Safety or Durability of CAR-T Products Without Requiring Chemotherapy GCAR Platform In vivo CAR therapy enabled with the CD3-Targeted LV and FITNESS DRIVER CD3-Targeted LV engineered to […]

Mature Manufacturing and Technology that Scales

“How do you build, manage, and grow global oncology teams in opposite time zones amidst a pandemic? It’s a question I asked myself as I accepted a new position eight months into the COVID-19 lockdown, knowing that my first interactions with a large part of our global teams would not be in person and that […]

Headline after headline, we hear about precision medicine and advances in the treatment of challenging diseases that were previously almost always fatal. And thanks to the accelerating scientific advancements in biotechnology, we’re successfully battling subsets of diseases that seemed unbeatable less than a decade ago. Cancer is one example of this trend. No sooner did […]

Link to article

Link to virtual “poster” presentation   Key Messages:   The current work describes a high-throughput method for screening lymphoproliferative elements in vivo in a lentivirus format for next generation CAR-T A “logic-gated” HER2-targeted CAR-T was designed that preferentially recognizes HER2 in the tumor microenvironment (TME), thereby limiting on-target toxicity of low HER2 levels expressed in […]

WEST PALM BEACH, Fla., April 17, 2023 — EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, presented a poster entitled “In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR T and NK-like (CAR-TaNK) cells capable of complete ablation of B […]

WEST PALM BEACH, Fla., Sept. 16, 2022 — EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, announced that pre-clinical data from its solid-tumor subcutaneous CAR therapy program will be presented at the virtual 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology hosted by the Center […]

EXUMA Biotech Presents Early Clinical and Translational Findings from Solid Tumor Cell Therapy and In Vivo CAR Engineering Research at the AACR Annual Meeting 2023 April 17, 2023 Read More Dr. Sid Kerkar speaks with CGT Live about how EXUMA’s TaNK platforms aim to make CAR therapy safer and faster through novel lentivector engineering October […]

mRNA encoding a CAR specific stimulating protein (CSSP) mediates tumor metabolism regulated (TMR) CAR signaling for CAR-T expansion beyond the tumor microenvironment. April 9, 2024 Read More In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR-T and NK-like (CAR-TaNK) cells capable of complete ablation of B cells in the blood, bone […]

Current Job Openings

We are reprogramming immune cells to target the most challenging autoimmune diseases and cancer Leadership Board of Directors Scientific Advisory Board

EXUMA Biotech is a clinical-stage biotech company advancing gene vector delivery to enhance patient access to innovative cell and gene therapies.